You just read:

Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors

News provided by

Blueprint Medicines Corporation

Nov 30, 2016, 06:01 EST